Bristol-Myers Squibb Co.

NYSE:BMY  
56.32
+0.90 (+1.63%)
Products

Bristol-Myers Squibb Says Phase 2 Data For Investigational Oral Factor Xia Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across A Wide Range Of Doses

Published: 11/15/2021 16:24 GMT
Bristol-Myers Squibb Co. (BMY) - Late-breaking Phase 2 Data for Investigational Oral Factor Xia Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses.
Bristol-myers - Milvexian Showed Efficacy & No Increase in Bleeding Across Doses, With No Major Bleeds in Milvexian Arms, When Compared With Enoxaparin.
Bristol-myers Squibb Co - Trial Met Both of Its Pre-specified Proof-of-principle Requirements.
Bristol-myers Squibb Co - at Daily Doses of at Least 100 Mg, Rates of Vte With Milvexian Were Significantly Lower Than With Enoxaparin.
Bristol-myers Squibb Co - Results From Ongoing Phase 2 Study of Milvexian for Secondary Stroke Prevention Are Expected in First Half of 2022.